Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging
- PMID: 32527549
- DOI: 10.1016/j.bmcl.2020.127248
Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging
Abstract
Non-invasive imaging of vascular endothelial growth factor receptor 1 (VEGFR1) remains a great challenge in the early diagnosis of tumors, especially in gastric cancer. Here, we designed and evaluated a novel 111In-DOTA-F56 peptide as a radioactive analogue of F56 (peptide WHSDMEWWYLLG) to bind VEGFR1. It was obtained by radiolabeling DOTA-F56 with 111InCl3 with 98% radiochemical purity and 1.4 ± 0.4 GBq/µmol specific activity. 111In-DOTA-F56 was obtained by the reaction of DOTA-F56 (10 µg) with 111InCl3 in pH 4.0 sodium acetate buffer at 85 °C for 20 min. 111In-DOTA-F56 shows good stability in 0.01 M Phosphate Buffered Saline (PBS) and 5% Human Serum Albumin (HSA). 111In-DOTA-F56 has a high binding affinity for human gastric cancer BGC-823 cells. Bio-distribution studies of 111In-DOTA-F56 were performed in nude mice xenografted with human gastric cancer BGC-823 cells and the results revealed tumor uptake accumulation. A blocking dose of DOTA-F56 significantly reduced the tumor uptake of 111In-DOTA-F56. Tumors were observed with Micro-SPECT images, and the uptake in the tumor increased with time from 4 h to 24 h. The MIP of the Micro-SPECT also showed that the excess DOTA-F56 can specifically block 111In-DOTA-F56 in a mouse tumor model. We successfully synthesized the 111In-DOTA-F56 VEGFR1-targeted peptide as a non-invasive molecule with fine radiochemical properties. Micro-SPECT indicates tumor uptake, which can be further blocked by excess of the F56 peptide, indicating that 111In-DOTA-F56 peptide has potential for early detection of VEGFR1 positive gastric cancer and is worthy of further clinical investigations.
Keywords: (111)In-DOTA-F56; DOTA-F56; Gastric cancer; Micro-SPECT imaging; VEGFR1.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
125I-F56 Peptide as Radioanalysis Agent Targeting VEGFR1 in Mice Xenografted with Human Gastric Tumor.ACS Med Chem Lett. 2017 Jan 20;8(2):266-269. doi: 10.1021/acsmedchemlett.6b00498. eCollection 2017 Feb 9. ACS Med Chem Lett. 2017. PMID: 28197324 Free PMC article.
-
Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer.Am J Cancer Res. 2015 Oct 15;5(11):3301-10. eCollection 2015. Am J Cancer Res. 2015. PMID: 26807312 Free PMC article.
-
Development of a novel albumin-based and maleimidopropionic acid-conjugated peptide with prolonged half-life and increased in vivo anti-tumor efficacy.Theranostics. 2018 Mar 7;8(8):2094-2106. doi: 10.7150/thno.22069. eCollection 2018. Theranostics. 2018. PMID: 29721065 Free PMC article.
-
68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.Nucl Med Biol. 2014 Mar;41(3):268-75. doi: 10.1016/j.nucmedbio.2013.12.008. Epub 2013 Dec 18. Nucl Med Biol. 2014. PMID: 24438818
-
Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.Mol Imaging Biol. 2019 Feb;21(1):130-139. doi: 10.1007/s11307-018-1207-x. Mol Imaging Biol. 2019. PMID: 29802552 Free PMC article.
Cited by
-
Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice.Int J Mol Sci. 2021 May 21;22(11):5459. doi: 10.3390/ijms22115459. Int J Mol Sci. 2021. PMID: 34064291 Free PMC article.
-
Clickable Radiocomplexes With Trivalent Radiometals for Cancer Theranostics: In vitro and in vivo Studies.Front Med (Lausanne). 2021 Jun 11;8:647379. doi: 10.3389/fmed.2021.647379. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34179038 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical